Physician
Solas Health PLLC
Solas Health PLLC was paid $13.33M by Medicaid between Jan 2018 and Dec 2024, across 29 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 35% of everything it billed.
33Billing provider infoSOLAS HEALTH PLLC
PINEHURST, NC 28374
PINEHURST, NC 28374
33aNPI1710046925assigned 12/06/2006
33bProvider typeAnesthesiology Physician
28Total paid$13.33M
24GClaims204,431
24DCodes billed29
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Anesthesiology Physician providers in North Carolina
Rank by total paid#1 of 52
Median peer was paid$26K
This provider vs. median509×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 13,205 | $815K | |
| 2019 | 21,008 | $1.35M | |
| 2020 | 27,364 | $2.19M | |
| 2021 | 34,948 | $2.53M | |
| 2022 | 38,995 | $2.44M | |
| 2023 | 37,559 | $2.21M | |
| 2024incomplete | 31,352 | $1.79M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 35% | 79,568 | 55,241 | $4.68M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 27% | 27,091 | 17,789 | $3.55M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 23% | 51,383 | 33,544 | $3.12M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 7.4% | 11,776 | 7,900 | $990K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.1% | 22,657 | 17,519 | $675K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,892 | 1,507 | $123K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 406 | 274 | $50K |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | <1% | 940 | 588 | $31K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | <1% | 321 | 257 | $28K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | <1% | 206 | 119 | $18K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,044 | 680 | $16K |
| 90837 | Psychotherapy session, about an hourPsychotherapy, 53 minutes with patient | <1% | 211 | 130 | $11K |
17 more codes
| 99203 | Doctor's office visit, new patient (routine) | <1% | 202 | $9K |
| 99199 | Unlisted special service, procedure or report | <1% | 1,928 | $6K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,446 | $4K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 79 | $3K |
| 20610 | <1% | 142 | $3K | |
| 99406 | <1% | 497 | $3K | |
| 62323 | <1% | 33 | $2K | |
| 99408 | <1% | 25 | $652.82 | |
| 77002 | <1% | 43 | $559.40 | |
| 96103 | <1% | 279 | $472.38 | |
| 96146 | <1% | 1,040 | $313.51 | |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | <1% | 90 | $291.90 |
| 81025 | <1% | 28 | $212.94 | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 375 | $60.50 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 115 | $58.47 |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | <1% | 493 | $36.42 |
| H0050 | Alcohol and/or drug services, brief intervention, per 15 minutes | 0% | 121 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCORRIGAN, FRANCIS (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Corrlabs, LLC | Southern Pines, NC | $4K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.